Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized, double-blind, placebo-controlled trial of nidufexor in diabetic nephropathy
2018-002491-40Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis comparing Nidufexor with Placebo (2 arms). Primary endpoint: Change in albuminuria versus placebo. Started Feb 2019; status: completed.
02
Drugs
nidufexor
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2018-002491-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002491-40.